| ASPVD | atherosclerotic peripheral vascular disease |
|---|---|
| BZRP | benzodiazepine receptor peripheral [type] |
| CSPINE | corticosteroid use, seropositive RA, peripheral joint destruction, involvement of cervical nerves, n... |
| FPR | false-positive rate; finger peripheral resistance; fluorescence photobleaching recovery; N-formylpep... |
| HPBL | human peripheral blood leukocyte |
Q blood group system
| nootropic agents | Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated. (12 Dec 1998) |
|---|---|
| sunscreening agents | Chemical or physical agents that protect the skin from sunburn and erythema by absorbing or blocking ultraviolet radiation. (12 Dec 1998) |
| sweetening agents | Substances that sweeten food, beverages, medications, etc., such as sugar, saccharine or other low-calorie synthetic products. (12 Dec 1998) |
| dentin-bonding agents | Cements that act through infiltration and polymerization within the dentinal matrix and are used for dental restoration. They can be adhesive resins themselves, adhesion-promoting monomers, or polymerization initiators that act in concert with other agents to form a dentin-bonding system. (12 Dec 1998) |
| dermatologic agents | Drugs used to treat or prevent skin disorders or for the routine care of skin. (12 Dec 1998) |
| dopamine agents | Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (12 Dec 1998) |
| imaging agents | Proteins developed to act as imaging or contrast agents for use with various types of bodyscanners. The proteins, usually antibodies, bind to specific tissue types, usually tumours, and allow the scanner to distinguish those tissues from the surrounding tissue very easily. (14 Nov 1997) |
| immunosuppressive agents | Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of suppressor T-cell populations or by inhibiting the activation of helper cells. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of interleukins and other cytokines are emerging. (12 Dec 1998) |
| intercalating agents | Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA. (12 Dec 1998) |
| iron chelating agents | Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of haemoglobin is an example of a metal chelate found in biological systems. (12 Dec 1998) |
| tocolytic agents | Drugs that prevent preterm labour and immature birth by suppressing uterine contractions. Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete. (12 Dec 1998) |
| embedding agents | Materials such as celloidin, paraffin, etc. In which specimens of tissue are set before being cut into sections for microscopic examination. (05 Mar 2000) |
| TRIC agents | Strains of Chlamydia trachomatis that cause trachoma and inclusion conjunctivitis agents See: Chlamydia trachomatis. (05 Mar 2000) |
| trypanocidal agents | Agents destructive to the protozoal organisms belonging to the suborder trypanosmatina. (12 Dec 1998) |
| excitatory amino acid agents | Drugs used for their actions on any aspect of excitatory amino acid neurotransmitter systems. Included are drugs that act on excitatory amino acid receptors, affect the life cycle of excitatory amino acid transmitters, or affect the survival of neurons using excitatory amino acids. (12 Dec 1998) |